Prescient Therapeutics Advances Cancer Therapy with FDA Fast Track

Prescient Therapeutics Limited ( (AU:PTX) ) has provided an update.

Prescient Therapeutics announced an investor briefing to discuss the next phase of their PTX-100 program, following the U.S. FDA’s fast track designation. The company is advancing its oncology pipeline with a planned Phase 2 study for PTX-100 in Cutaneous T cell lymphoma, highlighting its potential impact on cancer treatment and market positioning.

More about Prescient Therapeutics Limited

Prescient Therapeutics Limited is a clinical stage oncology company focused on developing personalized cancer therapies, including targeted and cellular therapies. Their primary products include PTX-100, a first-in-class compound targeting the cancer growth enzyme GGT-1, and various cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR, which enhance cell therapy performance and provide innovative approaches to cancer treatment.

YTD Price Performance: -16.00%

Average Trading Volume: 506,396

Technical Sentiment Signal: Buy

Current Market Cap: A$33.82M

See more data about PTX stock on TipRanks’ Stock Analysis page.